All In Biotech

Drug Trial Radar · NCT00755495

Safety and Efficacy of Ramelteon and Doxepin in Subjects With Chronic Insomnia

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Proof-of-Concept Study to Evaluate the Safety and Efficacy of Ramelteon Taken in Combination With Doxepin for the Treatment of Subjects With Chronic Insomnia

Last checked: Nov 19, 2026Latest source record: Feb 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 472 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

472

Actual

Start

Jul 2006

Primary completion

Mar 2007

Study completion Mar 2007

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Sep 19, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), combined with doxepin in treating subjects with insomnia.

Conditions

  • Sleep Initiation and Maintenance Disorders

Interventions

  • Ramelteon and doxepinDrug

    Ramelteon 8 mg, tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.

  • RamelteonDrug

    Ramelteon 8 mg, tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.

  • DoxepinDrug

    Ramelteon placebo-matching tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.

  • PlaceboDrug

    Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean wake time after persistent sleep onset during the double-blind Treatment Period, as measured by polysomnographyTime frame: Weeks 1, 3, and 5 or Final Visit

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.